Genmab — November 2020
-
And as disclosed in the abstract, by the time of the cut, the median follow-up was 8.3 months, and 25 patients were still ongoing. And I think that with this, I give you a signal, that 25 patients were still ongoing. And if you look at the data again at the tail, in above 48 milligrams for the DLBCL from 7 patients, the ORR was 100%; CR, 28%; 72% PRs, and those patients were ongoing. So – and the FPL, same thing, above 12. And the cut is arbitrary,
-
Thanks E L for the fantastic job you are doing
-
Yes, I must admit, I got carried away with Jans words again again...;-)
-
But I am sure they will deliver again
-
@E L What do you expect we will hear on fridag 13.?
-
Jan always points out Genmabs abilities to combine bispecific antibodies via robotics. Any idea why other Pharma companies can‘t copy?
-
He says they can produce thousands of samples in the same time as competitors produce a handful!
-
yes, maybe. but i don't expect new data @AaBforever , more of a deep dive into what we know and more explanation
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind